Project Details
Description
Project Summary
Although individuals diagnosed with COPD have high rates of nicotine dependence, depression, and anxiety, there is very limited understanding of the psychological risk factors that commonly drive these conditions and how they can be addressed through targeted behavioral treatment. The proposed research will develop a novel smoking cessation intervention among COPD patients and use qualitative data from patients and providers to guide treatment delivery. Findings will guide a randomized, controlled trial to test an intervention with far-reaching implications for improving behavioral health and reducing morbidity and mortality among COPD patients.
Abstract
Chronic Obstructive Pulmonary Disease (COPD) is caused primarily by smoking and smoking cessation is the first-line treatment for slowing disease progression. Despite this, nearly 50% of COPD patients continue to smoke following diagnosis. Smokers with COPD report high rates of co-occurring conditions – nicotine dependence, depression, and anxiety – which serve as barriers to quitting. The proposed research will conduct the development and preliminary testing of a behavioral intervention designed to target the common psychological factors underlying these co-occurring conditions and foster smoking cessation among COPD patients.
Primary aims of the proposed research are to: 1) Refine behavioral treatment components through qualitative interviews with patients and providers, and 2) Develop a tailored behavioral treatment to address psychological risk factors among COPD patients using single case design experiments. The proposed project will be the first to adapt a behavioral treatment to specifically target psychological risk factors among COPD patients who smoke. By addressing core psychological risk factors, the behavioral treatment may help buffer against stress associated with disease progression and increase COPD patients’ exercise tolerance, engagement in pulmonary rehabilitation, and quality of life. Thus, this intervention has potential to obviate a large number of health burdens among COPD patients, and ultimately to reduce morbidity and mortality associated with COPD.
Status | Finished |
---|---|
Effective start/end date | 7/1/17 → 6/30/19 |
Funding
- American Lung Association (SB-514748)
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.